ASCO 2016 | Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway
John Hainsworth
Press brief by John Hainsworth, MD of the Sarah Cannon Research Institute, Nashville, TN, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Related videos

Producing patient-specific tumor-reactive T-cells
Chiara Cattaneo

TNBC treatment: platinum-based therapy and PARP inhibition
Véronique Dieras

BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Véronique Dieras

Health-related QoL in ipilimumab treated advanced melanoma survivors
Christian Blank

OpACIN and OpACIN-neo trial updates
Christian Blank